Richard Jones
Director/Board Member at PEGASYSTEMS INC.
Net worth: 62 M $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alan Trefler | M | 68 | 41 years | |
| Helena H. Chaye | M | - |
Western Oncolytics Ltd.
 Western Oncolytics Ltd. Pharmaceuticals: MajorHealth Technology Western Oncolytics Ltd. develops novel therapies for cancer. The private company is based in Westlake. Helena H. Chaye has been the CEO of the American company since 2019.
Kalivir Immunotherapeutics, Inc.
 Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | 5 years |
| Ken Stillwell | M | 53 | 8 years | |
| Efstathios Kouninis | M | 62 | 16 years | |
| Sharon Rowlands | F | 65 | 8 years | |
| Dianne Ledingham | F | 61 | 8 years | |
| Christopher J. Lafond | M | 58 | 5 years | |
| Don Schuerman | M | - | 27 years | |
| Vernon Lawrence Weber | M | 67 | 12 years | |
| Stephen H. Thorne | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Dan Haefner | M | - |
Buyers Access LLC
 Buyers Access LLC Internet Software/ServicesTechnology Services Part of OMNIA Partners, Inc., Buyers Access LLC operates an online platform for purchasing analysis. The private company is based in Denver, CO. The company was founded in 1986. Dan Haefner has been the CEO of the company since 2017. Buyers Access was acquired by OMNIA Partners, Inc. on December 02, 2021. | 7 years |
| Leon Trefler | M | 63 | 26 years | |
| Peter Gyenes | M | 78 | 15 years | |
| Grant McFadden | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | 1 years |
| Matthew J. Cushing | M | 54 | 7 years | |
| Dylan Glenn | M | 55 |
Episcopal High School
| - |
| Pete Roden | M | - |
Buyers Access LLC
Buyers Access LLC Internet Software/ServicesTechnology Services Part of OMNIA Partners, Inc., Buyers Access LLC operates an online platform for purchasing analysis. The private company is based in Denver, CO. The company was founded in 1986. Dan Haefner has been the CEO of the company since 2017. Buyers Access was acquired by OMNIA Partners, Inc. on December 02, 2021. | - |
| Kerim Akgonul | M | - | - | |
| Craig Dixon | M | 48 |
Episcopal High School
| - |
| Carlos Fuentes | M | - | 5 years | |
| Fahd Beg | M | 45 |
Episcopal High School
| - |
| Ned Smith | M | - |
Episcopal High School
| - |
| Katherine Parente | F | - | 2 years | |
| Pat Dwyer | M | - | 6 years | |
| Sean Audet | M | - | - | |
| Joaquin Reixa | M | - | - | |
| Kurt Rote | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| John Higgins | M | - | - | |
| Kikelomo Belizaire | M | - | 2 years | |
| Christian Guttmann | M | 49 | 1 years | |
| Steve Bixby | M | - | 25 years | |
| Jon Wigginton | M | 62 |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Jeff Taylor | M | - | 6 years | |
| Michael Pyle | M | 69 | 39 years | |
| Frank Guerrera | M | - | 7 years | |
| Bailey Patrick | M | 62 |
Episcopal High School
| - |
| Haag Sherman | M | 58 |
Episcopal High School
| - |
| Thomas Carter | M | 72 |
Episcopal High School
| 20 years |
| Thad Hill | M | 56 |
Episcopal High School
| - |
| Scot J. Luther | M | 61 |
Episcopal High School
| - |
| John Weinzierl | M | 56 |
Episcopal High School
| - |
| Steven Gross | M | - | 7 years | |
| James H. Cohen | M | - |
Episcopal High School
| - |
| Tom Leonard | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Terry Hermiston | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Henry D. Jones | M | 63 |
Episcopal High School
| - |
| Steven Lilly | M | 54 |
Episcopal High School
| - |
| Lisa Pintchman Rogers | F | - | 10 years | |
| William Randall | M | 57 |
Episcopal High School
| - |
| Peter Welburn | M | - | - |
Connections Chart
Multi-company connection
Former connections
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Jones
- Personal Network
